Moss, 10 April 2026
Reference is made to Gentian Diagnostics ASA's stock exchange announcement on 12
March 2026 regarding the result of the offer under the Employee Share Purchase
Program and the related share capital increase.
The share capital increase pertaining to the Employee Share Purchase Program has
today been registered with the Norwegian Register of Business Enterprises (Nw.:
Foretaksregisteret). The new registered share capital of the company is NOK
1,545,862.40, divided into 15,458,624 shares, each with a nominal value of NOK
0.10. Upon registration with the Norwegian Central Securities Depository (VPS),
the new shares will be listed on the Oslo Stock Exchange.
For further information, please contact:
IR contact:
Njaal Kind, CFO
njaal.kind@gentian.no
+47 919 06 525 (mobile)
This information is subject to the disclosure requirements pursuant to Section
5-12 of the Norwegian Securities Trading Act.
About Gentian Diagnostics
Gentian Diagnostics (OSE: GENT), develops and manufactures high-quality, in
vitro diagnostic reagents. Our mission is to innovate diagnostic efficiency for
better treatment decisions. Gentian's expertise and focus lie within
immunoassays, specifically for infections, inflammation, kidney disease and
heart failure. By converting existing and clinically relevant biomarkers to the
most efficient, high-throughput analysers, the company contributes to saving
costs and protecting life. Gentian Diagnostics is headquartered in Moss, Norway,
serving the global human and veterinary diagnostics markets through sales and
representative offices in Sweden, USA, and China. For more information, please
visit www.gentian.com.